Annals of surgical oncology
-
Randomized Controlled Trial Clinical Trial
Dextromethorphan mitigates phantom pain in cancer amputees.
Hyperexcitability of N-methyl-D-aspartate (NMDA) receptors may play a role in the persistence of phantom pain. Dextromethorphan (DM) blocks NMDA receptors. ⋯ Persistent phantom pain probably involves NMDA receptor hyperexcitability because DM 120 to 270 mg/day mitigated the pain satisfactorily.